![](/images/graphics-bg.png)
Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Joint Authors
Lee, Jeong-Hoon
Yoon, Jung-Hwan
Cho, Eun Ju
Yu, Su Jong
Kim, Yoon Jun
Chung, Sung Won
Chang, Young
Lee, Hyo Young
Source
Gastroenterology Research and Practice
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-16
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aim.
The efficacy of tenofovir disoproxil fumarate (TDF) monotherapy as maintenance therapy in multidrug-resistant (MDR) hepatitis B virus (HBV) patients after complete virologic suppression (CVS) has not been well evaluated.
We evaluated the efficacy of maintenance TDF monotherapy compared with conventional TDF plus entecavir combination therapy after CVS of MDR HBV.
Methods.
In this single-center retrospective study, patients with MDR HBV who were previously treated with entecavir plus TDF combination therapy and achieved CVS were included.
Patients were either maintained on entecavir plus TDF combination therapy or switched to TDF monotherapy after CVS.
The primary endpoint was the virologic breakthrough, and secondary outcomes were liver cirrhosis (LC) or hepatocellular carcinoma (HCC) development.
To overcome immortal time bias, time-varying Cox proportional hazard regression analysis was performed.
Results.
A total of 201 patients were included, and 153 patients were maintained on entecavir plus TDF combination therapy (combination group); 48 patients were converted from combination therapy to TDF monotherapy (single group) after CVS.
Five patients experienced a virologic breakthrough, one patient in the single group owing to poor transient compliance and four patients in the combination group (P=0.51).
One new case of LC developed in the single group; five cases of LC developed in the combination group (P=0.35).
No new HCC development occurred in the single group, while seven cases of HCC developments were noted in the combination group.
However, these results were not statistically significant (P=0.54).
Conclusions.
For patients with suppressed HBV DNA, the efficacy of TDF monotherapy as maintenance therapy is comparable to that of entecavir plus TDF combination therapy.
American Psychological Association (APA)
Chung, Sung Won& Chang, Young& Lee, Hyo Young& Cho, Eun Ju& Lee, Jeong-Hoon& Yu, Su Jong…[et al.]. 2018. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1165422
Modern Language Association (MLA)
Chung, Sung Won…[et al.]. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1165422
American Medical Association (AMA)
Chung, Sung Won& Chang, Young& Lee, Hyo Young& Cho, Eun Ju& Lee, Jeong-Hoon& Yu, Su Jong…[et al.]. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1165422
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1165422